

FDA's Role in Dietary Supplement Regulation

Gerie Voss, J.D.

Acting Director, Division of Policy and Regulations Implementation FDA/CFSAN/Office of Dietary Supplement Programs (ODSP)



Agenda

Regulatory Framework for Dietary Supplements

ODSP's Priorities

FDA's Steps to Modernize Regulation of Dietary Supplements

www.fda.gov

2



Definition of Dietary Supplement

- Product (other than tobacco) that is intended to supplement the diet
- Product that is intended for ingestion
- Contains one or more dietary ingredients
 - Vitamin
 - Mineral
 - Herb or other botanical
 - Amino acid

- Dietary substance for use by man to supplement the diet by increasing the total dietary intake
- A concentrate, metabolite, constituent, extract, or combination of any of the above dietary ingredients

Distinguished from Drugs and Conventional Foods



- Does not include an article that is approved as a new drug, antibiotic, or biologic, or has been authorized for investigation
 - Unless the article was marketed as a dietary supplement or as a food before such approval or authorization. (FDCA §201(ff)(3))
- Dietary supplements may not be:
 - Represented for use as conventional food or as "sole item of a meal or the diet"



Regulatory Responsibilities

- Facility Registration
- New Dietary Ingredient Notification
- Dietary Supplement Labeling
 - Structure/Function Notification
- Current Good Manufacturing Practices
- Adverse Event Reporting



Facility Registration

- All food facilities must register with FDA
 - Domestic and foreign
 - Basic information: name, address, type of facility, responsible party
- Renewal of information every evennumbered year



New Dietary Ingredient Notifications

- FD&C Act 413(a)(2)
 - Established the requirement that manufacturers or distributors must submit a notification to FDA 75 days prior to introducing a new ingredient to market
 - NDI notifications must meet the requirements of 21 CFR 190.6 to be considered complete
 - Not an approval



Dietary Supplement Labeling

- Must be labeled as a "dietary supplement"
- Must list all ingredients
- Properly formatted Supplement Facts label
- Name/location of manufacturer
- Domestic contact information for submission of adverse events
- Permissible claims

FDA

Permissible Claims and Structure/Function Notifications

- Claims made in accordance with section 403(r)(6) of the FD&C Act
 - Nutrient deficiency disease claim
 - General well-being claim
 - Structure/function claim
- Firms are required to:
 - Maintain adequate *substantiation*
 - include disclaimer language
 - notify FDA no later than 30 days *after* marketing the product containing the claim



Current Good Manufacturing Practices

- Apply to all firms who manufacture, package, label or hold dietary supplements
 - Domestic and foreign
- To help ensure dietary supplement product quality, purity, consistency, and safety
 - Production and process controls
 - Testing requirements for raw materials and finished products
- Compliance confirmed by FDA inspections



Adverse Event Reporting

- Manufacturers:
 - Submit serious adverse events to FDA
 - Maintain records of adverse events
- Follow-up
 - AERs entered into the CFSAN Adverse Event Reporting System (CAERS) database for review/evaluation.
 - CAERS raw data available:
 https://www.fda.gov/food/complianceenforcement/ucm494015.htm#files



ODSP Priorities

Our three strategic priorities align with reasonable consumer expectations:

- Consumer safety
 - Expectation: this product will not cause illness, injury, or death
- Product integrity
 - Expectation: this product contains what the label says, in the fair amounts, and nothing else
- Informed decision-making
 - Expectation: this is some scientific basis to believe that this product will have the effect that it claims



ODSP Priorities

- Structure/function claim notifications, NDINs, and adverse event reports
- Warning letters regarding violative ingredients and disease claims
- Injunctions for violations of CGMPs
- Seizure of violative product




Steps to Modernize Regulation

- Achieve right balance between:
 - Preserving consumers' access to lawful supplements, while still upholding obligation to protect the public from unsafe and unlawful products
 - Holding accountable those actors who are unable or unwilling to comply with the requirements of the law

Steps to Modernize Regulation (continued)



- FDA launched Dietary Supplement Ingredient Advisory List
- In May 2019, FDA hosted a public meeting on Responsible Innovation in Dietary Supplements
- The Botanical Safety Consortium (BSC) was announced in November 2019





- Engaging in a public discussion
- Mandatory Product Listing
 - Improve transparency
 - Preserve DSHEA's original vision
 - Strategic use of FDA's resources



Thank you

Office of Dietary Supplement Programs, CFSAN, FDA
Gerie Voss, J.D., Acting Director
Division of Regulations and Policy Implementation
ODSP@FDA.HHS.GOV